Endocrine Abstracts

Recent years have seen an increasing effort to decode the cancer genome. Most of the studies have focused on the coding genome to identify cancer driver genes. My group is interested in the role of the non-coding genome and its potential contribution to the drive transcriptional aberrations in breast cancer patients. To do so we use a wide-spectrum of techniques including genomic, epigenomics in patient-derived samples. I will present the results of a couple of studies in which mapping the non-coding genome using epigenomic has yield novel insights on cancer progression in luminal breast cancer patients.